Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125-1 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea
Antimicrobial resistance in Neisseria gonorrhoeae is threatening the gonorrhoea treatment, and optimizations of the current ceftriaxone-treatment regimens are crucial. We evaluated the pharmacodynamics of ceftriaxone single-dose therapy (0.125-1 g) against ceftriaxone-susceptible and ceftriaxone-res...
Saved in:
| Published in: | Journal of antimicrobial chemotherapy Vol. 79; no. 5; p. 1006 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
02.05.2024
|
| ISSN: | 1460-2091, 1460-2091 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Antimicrobial resistance in Neisseria gonorrhoeae is threatening the gonorrhoea treatment, and optimizations of the current ceftriaxone-treatment regimens are crucial. We evaluated the pharmacodynamics of ceftriaxone single-dose therapy (0.125-1 g) against ceftriaxone-susceptible and ceftriaxone-resistant gonococcal strains, based on EUCAST ceftriaxone-resistance breakpoint (MIC > 0.125 mg/L), in our hollow fibre infection model (HFIM) for gonorrhoea.
Gonococcal strains examined were WHO F (ceftriaxone-susceptible, MIC < 0.002 mg/L), R (ceftriaxone-resistant, MIC = 0.5 mg/L), Z (ceftriaxone-resistant, MIC = 0.5 mg/L) and X (ceftriaxone-resistant, MIC = 2 mg/L). Dose-range HFIM 7 day experiments simulating ceftriaxone 0.125-1 g single-dose intramuscular regimens were conducted.
Ceftriaxone 0.125-1 g single-dose treatments rapidly eradicated WHO F (wild-type ceftriaxone MIC). Ceftriaxone 0.5 and 1 g treatments, based on ceftriaxone human plasma pharmacokinetic parameters, eradicated most ceftriaxone-resistant gonococcal strains (WHO R and Z), but ceftriaxone 0.5 g failed to eradicate WHO X (high-level ceftriaxone resistance). When simulating oropharyngeal gonorrhoea, ceftriaxone 0.5 g failed to eradicate all the ceftriaxone-resistant strains, while ceftriaxone 1 g eradicated WHO R and Z (low-level ceftriaxone resistance) but failed to eradicate WHO X (high-level ceftriaxone resistance). No ceftriaxone-resistant mutants were selected using any ceftriaxone treatments.
Ceftriaxone 1 g single-dose intramuscularly cure most of the anogenital and oropharyngeal gonorrhoea cases caused by the currently internationally spreading ceftriaxone-resistant gonococcal strains, which should be further confirmed clinically. A ceftriaxone 1 g dose (±azithromycin 2 g) should be recommended for first-line empiric gonorrhoea treatment. This will buy countries some time until novel antimicrobials are licensed. Using ceftriaxone 1 g gonorrhoea treatment, the EUCAST ceftriaxone-resistance breakpoint is too low. |
|---|---|
| AbstractList | Antimicrobial resistance in Neisseria gonorrhoeae is threatening the gonorrhoea treatment, and optimizations of the current ceftriaxone-treatment regimens are crucial. We evaluated the pharmacodynamics of ceftriaxone single-dose therapy (0.125-1 g) against ceftriaxone-susceptible and ceftriaxone-resistant gonococcal strains, based on EUCAST ceftriaxone-resistance breakpoint (MIC > 0.125 mg/L), in our hollow fibre infection model (HFIM) for gonorrhoea.
Gonococcal strains examined were WHO F (ceftriaxone-susceptible, MIC < 0.002 mg/L), R (ceftriaxone-resistant, MIC = 0.5 mg/L), Z (ceftriaxone-resistant, MIC = 0.5 mg/L) and X (ceftriaxone-resistant, MIC = 2 mg/L). Dose-range HFIM 7 day experiments simulating ceftriaxone 0.125-1 g single-dose intramuscular regimens were conducted.
Ceftriaxone 0.125-1 g single-dose treatments rapidly eradicated WHO F (wild-type ceftriaxone MIC). Ceftriaxone 0.5 and 1 g treatments, based on ceftriaxone human plasma pharmacokinetic parameters, eradicated most ceftriaxone-resistant gonococcal strains (WHO R and Z), but ceftriaxone 0.5 g failed to eradicate WHO X (high-level ceftriaxone resistance). When simulating oropharyngeal gonorrhoea, ceftriaxone 0.5 g failed to eradicate all the ceftriaxone-resistant strains, while ceftriaxone 1 g eradicated WHO R and Z (low-level ceftriaxone resistance) but failed to eradicate WHO X (high-level ceftriaxone resistance). No ceftriaxone-resistant mutants were selected using any ceftriaxone treatments.
Ceftriaxone 1 g single-dose intramuscularly cure most of the anogenital and oropharyngeal gonorrhoea cases caused by the currently internationally spreading ceftriaxone-resistant gonococcal strains, which should be further confirmed clinically. A ceftriaxone 1 g dose (±azithromycin 2 g) should be recommended for first-line empiric gonorrhoea treatment. This will buy countries some time until novel antimicrobials are licensed. Using ceftriaxone 1 g gonorrhoea treatment, the EUCAST ceftriaxone-resistance breakpoint is too low. Antimicrobial resistance in Neisseria gonorrhoeae is threatening the gonorrhoea treatment, and optimizations of the current ceftriaxone-treatment regimens are crucial. We evaluated the pharmacodynamics of ceftriaxone single-dose therapy (0.125-1 g) against ceftriaxone-susceptible and ceftriaxone-resistant gonococcal strains, based on EUCAST ceftriaxone-resistance breakpoint (MIC > 0.125 mg/L), in our hollow fibre infection model (HFIM) for gonorrhoea.BACKGROUNDAntimicrobial resistance in Neisseria gonorrhoeae is threatening the gonorrhoea treatment, and optimizations of the current ceftriaxone-treatment regimens are crucial. We evaluated the pharmacodynamics of ceftriaxone single-dose therapy (0.125-1 g) against ceftriaxone-susceptible and ceftriaxone-resistant gonococcal strains, based on EUCAST ceftriaxone-resistance breakpoint (MIC > 0.125 mg/L), in our hollow fibre infection model (HFIM) for gonorrhoea.Gonococcal strains examined were WHO F (ceftriaxone-susceptible, MIC < 0.002 mg/L), R (ceftriaxone-resistant, MIC = 0.5 mg/L), Z (ceftriaxone-resistant, MIC = 0.5 mg/L) and X (ceftriaxone-resistant, MIC = 2 mg/L). Dose-range HFIM 7 day experiments simulating ceftriaxone 0.125-1 g single-dose intramuscular regimens were conducted.METHODSGonococcal strains examined were WHO F (ceftriaxone-susceptible, MIC < 0.002 mg/L), R (ceftriaxone-resistant, MIC = 0.5 mg/L), Z (ceftriaxone-resistant, MIC = 0.5 mg/L) and X (ceftriaxone-resistant, MIC = 2 mg/L). Dose-range HFIM 7 day experiments simulating ceftriaxone 0.125-1 g single-dose intramuscular regimens were conducted.Ceftriaxone 0.125-1 g single-dose treatments rapidly eradicated WHO F (wild-type ceftriaxone MIC). Ceftriaxone 0.5 and 1 g treatments, based on ceftriaxone human plasma pharmacokinetic parameters, eradicated most ceftriaxone-resistant gonococcal strains (WHO R and Z), but ceftriaxone 0.5 g failed to eradicate WHO X (high-level ceftriaxone resistance). When simulating oropharyngeal gonorrhoea, ceftriaxone 0.5 g failed to eradicate all the ceftriaxone-resistant strains, while ceftriaxone 1 g eradicated WHO R and Z (low-level ceftriaxone resistance) but failed to eradicate WHO X (high-level ceftriaxone resistance). No ceftriaxone-resistant mutants were selected using any ceftriaxone treatments.RESULTSCeftriaxone 0.125-1 g single-dose treatments rapidly eradicated WHO F (wild-type ceftriaxone MIC). Ceftriaxone 0.5 and 1 g treatments, based on ceftriaxone human plasma pharmacokinetic parameters, eradicated most ceftriaxone-resistant gonococcal strains (WHO R and Z), but ceftriaxone 0.5 g failed to eradicate WHO X (high-level ceftriaxone resistance). When simulating oropharyngeal gonorrhoea, ceftriaxone 0.5 g failed to eradicate all the ceftriaxone-resistant strains, while ceftriaxone 1 g eradicated WHO R and Z (low-level ceftriaxone resistance) but failed to eradicate WHO X (high-level ceftriaxone resistance). No ceftriaxone-resistant mutants were selected using any ceftriaxone treatments.Ceftriaxone 1 g single-dose intramuscularly cure most of the anogenital and oropharyngeal gonorrhoea cases caused by the currently internationally spreading ceftriaxone-resistant gonococcal strains, which should be further confirmed clinically. A ceftriaxone 1 g dose (±azithromycin 2 g) should be recommended for first-line empiric gonorrhoea treatment. This will buy countries some time until novel antimicrobials are licensed. Using ceftriaxone 1 g gonorrhoea treatment, the EUCAST ceftriaxone-resistance breakpoint is too low.CONCLUSIONSCeftriaxone 1 g single-dose intramuscularly cure most of the anogenital and oropharyngeal gonorrhoea cases caused by the currently internationally spreading ceftriaxone-resistant gonococcal strains, which should be further confirmed clinically. A ceftriaxone 1 g dose (±azithromycin 2 g) should be recommended for first-line empiric gonorrhoea treatment. This will buy countries some time until novel antimicrobials are licensed. Using ceftriaxone 1 g gonorrhoea treatment, the EUCAST ceftriaxone-resistance breakpoint is too low. |
| Author | Golparian, Daniel Unemo, Magnus Kong, Fabian Y S Oxelbark, Joakim Jacobsson, Susanne Brown, David Louie, Arnold Drusano, George |
| Author_xml | – sequence: 1 givenname: Magnus orcidid: 0000-0003-1710-2081 surname: Unemo fullname: Unemo, Magnus organization: Institute for Global Health, University College London (UCL), London, UK – sequence: 2 givenname: Daniel surname: Golparian fullname: Golparian, Daniel organization: Department of Laboratory Medicine, Faculty of Medicine and Health, WHO Collaborating Centre for Gonorrhoea and other STIs, National Reference Laboratory for Sexually Transmitted Infections, Örebro University, Örebro, Sweden – sequence: 3 givenname: Joakim surname: Oxelbark fullname: Oxelbark, Joakim organization: Division of Clinical Chemistry, Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden – sequence: 4 givenname: Fabian Y S orcidid: 0000-0002-9349-3080 surname: Kong fullname: Kong, Fabian Y S organization: Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia – sequence: 5 givenname: David surname: Brown fullname: Brown, David organization: Institute for Therapeutic Innovation, College of Medicine, University of Florida, Gainesville, FL, USA – sequence: 6 givenname: Arnold orcidid: 0000-0001-6227-7580 surname: Louie fullname: Louie, Arnold organization: Institute for Therapeutic Innovation, College of Medicine, University of Florida, Gainesville, FL, USA – sequence: 7 givenname: George orcidid: 0000-0001-9162-7332 surname: Drusano fullname: Drusano, George organization: Institute for Therapeutic Innovation, College of Medicine, University of Florida, Gainesville, FL, USA – sequence: 8 givenname: Susanne surname: Jacobsson fullname: Jacobsson, Susanne organization: Department of Laboratory Medicine, Faculty of Medicine and Health, WHO Collaborating Centre for Gonorrhoea and other STIs, National Reference Laboratory for Sexually Transmitted Infections, Örebro University, Örebro, Sweden |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38497988$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVUU1P3DAQtRAVsMCJO_IRDgEnTuL4iBC0lRDtoZxXE2e8a3DsxXaAvfXSH9lrf0ktPqTlNKP35s17o5mRbecdEnJUsrOSSX5-D-p8eABkLd8ie2XdsqJistze6HfJLMZ7xljbtN0O2eVdLYXsuj3y9-cSwgjKD2sHo1EUn8BOkIx31GuqUKdg4CU70mjcwmIx-Ig0LTHAak1PcoaqKcp_v_8sTmnyNMODUZBwU1rEKSpcJdNbpOCGT1zAaGICl-gtmhgx43ThnQ9h6RGybQpgXKTGUaBLb61_ptr0ATOiUb0mHf2AlmofNpQH5IsGG_Hwve6Tu-urX5ffipsfX79fXtwUilciFZzLWggNui-Z0EKqWigpWs0HrqQEXreZl7yvG9aXvGNSiEb1wJhsdKu1rvbJydveVfCPE8Y0H02-1lpw6Kc4r2QrWNOIrsqjx--jUz_iMF8FM0JYzz_eUf0H2FqUow |
| CitedBy_id | crossref_primary_10_1016_j_lanwpc_2025_101663 crossref_primary_10_1080_14787210_2024_2401560 crossref_primary_10_1093_cid_ciaf456 crossref_primary_10_1016_j_lanwpc_2024_101125 crossref_primary_10_1128_aac_00017_25 crossref_primary_10_1136_sextrans_2024_056405 crossref_primary_10_1080_14787210_2025_2499471 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. |
| Copyright_xml | – notice: The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. |
| DBID | NPM 7X8 |
| DOI | 10.1093/jac/dkae063 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1460-2091 |
| ExternalDocumentID | 38497988 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Örebro County Council Research Committee |
| GroupedDBID | --- -E4 .2P .I3 .XZ .ZR 0R~ 18M 1TH 29J 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 70D AABZA AACZT AAJKP AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAVAP AAWTL ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABPQP ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABZBJ ACCCW ACGFO ACGFS ACIWK ACPRK ACUFI ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFRAH AFXAL AGINJ AGKEF AGORE AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS ECGQY EE~ EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HH5 HW0 HZ~ IOX J21 JXSIZ KAQDR KOP KQ8 KSI KSN L7B M-Z MHKGH ML0 N9A NGC NOMLY NOYVH NPM NU- O9- OAUYM OAWHX OBS OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX RUSNO RW1 RXO TCURE TEORI TJX TMA TR2 W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ~91 7X8 |
| ID | FETCH-LOGICAL-c327t-339477fafb107f79c47c976f3d3c99a34694793b450b13809775cba0095f6fff2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 9 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001186493700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1460-2091 |
| IngestDate | Wed Oct 01 14:47:43 EDT 2025 Mon Jul 21 05:48:47 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c327t-339477fafb107f79c47c976f3d3c99a34694793b450b13809775cba0095f6fff2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-9349-3080 0000-0001-6227-7580 0000-0001-9162-7332 0000-0003-1710-2081 |
| PMID | 38497988 |
| PQID | 2967055782 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2967055782 pubmed_primary_38497988 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-05-02 |
| PublicationDateYYYYMMDD | 2024-05-02 |
| PublicationDate_xml | – month: 05 year: 2024 text: 2024-05-02 day: 02 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Journal of antimicrobial chemotherapy |
| PublicationTitleAlternate | J Antimicrob Chemother |
| PublicationYear | 2024 |
| SSID | ssj0006568 |
| Score | 2.4881234 |
| Snippet | Antimicrobial resistance in Neisseria gonorrhoeae is threatening the gonorrhoea treatment, and optimizations of the current ceftriaxone-treatment regimens are... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1006 |
| Title | Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125-1 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38497988 https://www.proquest.com/docview/2967055782 |
| Volume | 79 |
| WOSCitedRecordID | wos001186493700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaAItQLj_IqLw0SqkCqtZvYieMTQoiKA13toaC9rfxsF1Zxu94C-0v5O4ydrFIOSEhcIiWRFUuejL8Zf_MNIa-04MoxzaiuMFblid_YVCWnJqUgrasrnatcv3wSk0kzm8lpn3CLPa1y6xOzo7bBpBz5qJR1En7BDe3t-QVNXaPS6WrfQuM62WEIZRKlS8wGtfC6L4Xj9RitQRZ9fR4G8aOvyozsN-XGSf_zb9gy7zFHd_53dnfJ7R5dwrvOHO6Ra67dI7eO-_PzPXIw7ZSqN4dwMhRexUM4gOmgYb25T35tb23XsR4GVXAIHozzqd3Hz9A6SMmGpaM2RAddNdcGXic9iYoWcPoG1gHwoc21dlcH0ngZM6dGLx2o1v7xbuViArbtGiYuMwYWCk5DG1ars-AUfjS3toiwaEEBOvBl-AEeI38HW3ZZC7nJDyAovzLyAfl89OHk_Ufa94CghpViTRmTXAivvMY41QtpuDCIoDyzzEipGEb3KTeoeTXWBWvGCGcro1VCjr723pcPyY0W5_2YgHJFY3UhWOMZ98JKLa0sdcl4pbjhfp-83K7tHP-xdHCiWhcu43xY3X3yqDOQ-XknBjJnDZdJ8-3JP4x-SnZLxESZL1k-IzsePYx7Tm6a7-tFXL3IxovXyfT4NwFc_8c |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacodynamic+evaluation+of+ceftriaxone+single-dose+therapy+%280.125-1%E2%80%85g%29+to+eradicate+ceftriaxone-susceptible+and+ceftriaxone-resistant+Neisseria+gonorrhoeae+strains+in+a+hollow+fibre+infection+model+for+gonorrhoea&rft.jtitle=Journal+of+antimicrobial+chemotherapy&rft.au=Unemo%2C+Magnus&rft.au=Golparian%2C+Daniel&rft.au=Oxelbark%2C+Joakim&rft.au=Kong%2C+Fabian+Y+S&rft.date=2024-05-02&rft.eissn=1460-2091&rft_id=info:doi/10.1093%2Fjac%2Fdkae063&rft_id=info%3Apmid%2F38497988&rft_id=info%3Apmid%2F38497988&rft.externalDocID=38497988 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2091&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2091&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2091&client=summon |